AAV Factor VIII Vectors for Hemophilia A Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adeno-associated virus (AAV) vectors face limitations in packaging large therapeutic genes like Factor VIII due to size constraints, leading to truncated genes and reduced efficacy in gene therapy for hemophilia A.
Innovation Solution
Development of AAV vectors encoding functionally active Factor VIII protein, with optimized nucleic acid sequences and promoter elements, allowing for complete packaging and high expression activity, including the use of the SQ sequence and liver-specific transcription regulatory elements, to overcome size limitations and enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used to deliver therapeutic genes, then gene therapy efficacy is improved, but the vector size is limited to about 4.4 kb of protein-coding sequence
Solution Approach 1:
The Factor VIII gene is divided into two separate AAV vectors: one encoding the heavy chain (A domain) and another encoding the light chain (C domain). This segmentation allows each vector to remain within the 4.4 kb packaging capacity while collectively delivering the complete therapeutic gene functionality through complementary expression in target cells.
Solution Approach 2:
The patent employs nested structural organization where the Factor VIII coding sequence is embedded within the AAV vector backbone structure, which includes inverted terminal repeats (ITRs) and regulatory elements. This nesting allows maximization of the coding capacity within the constrained vector size by efficiently arranging functional elements.
2Quantity of substance
If the Factor VIII gene is packaged into AAV vectors, then complete gene delivery is achieved, but the central B domain must be deleted to fit size constraints
Solution Approach 1:
The central B domain of the Factor VIII gene is extracted and removed to create a truncated version that fits within AAV vector size limits. This extraction allows the essential A and C domains to be delivered while eliminating the non-essential B domain, achieving complete functional gene delivery within size constraints.
Solution Approach 2:
Instead of attempting to compress the complete Factor VIII gene into a single vector, the patent inverts the approach by splitting the gene into two separate vectors that each contain portions of the coding sequence. This inversion of the packaging strategy allows complete gene delivery without requiring extreme compression or deletion of critical domains.
3Length of moving object
If two separate AAV vectors are used to encode heavy and light chains, then size constraints are satisfied, but vector complexity and administration complexity increase
Solution Approach 1:
The patent merges the functionality of two separate AAV vectors into a single vector construct that contains both the heavy chain and light chain coding sequences. This combining approach maintains compliance with packaging capacity limits while simplifying the delivery system to a single vector, reducing administrative complexity compared to sequential dual-vector administration.
Data Source
AI summary
The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.